Pfizer has filed two petitions for IPR of U.S. Patent 8,591,897, owned by Genentech: IPR2017-01726 and IPR2017-01727. According to the petitions, the ‘897 patent is directed to methods for treating patients with non-metastatic HER2-positive breast cancer by administering anthracycline/cyclophosphamide (AC) based chemotherapy, followed by sequential administration of a taxoid and trastuzumab. The ‘897 patent is also the subject of IPR2017-00959, filed by Celltrion, which is pending an institution decision by the Board.
Trastuzumab is sold by Genentech under the trade-name Herceptin®.
Pfizer and its affiliate, Hospira, together have seven other pending IPRs on patents related to trastuzumab, as listed on our IPR tracker page.
The post Pfizer Files Two Petitions for IPR of Genentech’s Trastuzumab Patent appeared first on Big Molecule Watch.